Latest Ratios: P/E Ratio -10.3x · EV/EBITDA N/A · ROE -368.2%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.4B | $639M | $425M | $397M | $295M | $1.0B | $571M | $664M | $183M | — | — |
| Enterprise Value | $1.4B | $662M | $406M | $356M | $271M | $934M | $384M | $460M | $115M | — | — |
| P/E Ratio → | -10.32 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 16.68 | 7.86 | 12.78 | 28.29 | 18.50 | 27.79 | 36.70 | 49.95 | — | — | — |
| P/B Ratio | — | — | 6.27 | 2.87 | 2.50 | 5.65 | 2.39 | 3.48 | 2.25 | — | — |
| P/FCF | — | — | — | — | — | — | — | 60.00 | — | — | — |
| P/OCF | — | — | — | — | — | — | — | 33.12 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 8.14 | 12.21 | 25.41 | 17.04 | 24.77 | 24.67 | 34.60 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 41.56 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.0% | 94.0% | 28.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating Margin | -130.2% | -130.2% | -493.4% | -977.8% | -730.9% | -193.0% | -401.9% | -438.4% | — | — | — |
| Net Profit Margin | -140.3% | -140.3% | -444.1% | -599.5% | -814.2% | -211.0% | -372.6% | -411.9% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -368.2% | -368.2% | -143.5% | -65.7% | -85.5% | -37.5% | -27.0% | -40.3% | -491.9% | — | — |
| ROA | -44.4% | -44.4% | -49.6% | -26.1% | -40.6% | -23.3% | -16.9% | -26.0% | -135.0% | -128.3% | -86.4% |
| ROIC | -241.1% | -241.1% | -167.7% | -106.9% | -105.2% | -88.9% | -246.7% | — | -450.1% | — | — |
| ROCE | -64.1% | -64.1% | -70.1% | -55.3% | -47.7% | -25.9% | -21.4% | -32.7% | -182.0% | -302.3% | -121.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 1.25 | 0.65 | 0.78 | 0.13 | 0.09 | 0.12 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.28 | -0.29 | -0.20 | -0.61 | -0.79 | -1.07 | -0.84 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -18.44 | — | — | — |
| Interest Coverage | -8.69 | -8.69 | -10.14 | -5.34 | -25.21 | -275.25 | -415.60 | -1125.19 | -2336.42 | -739.21 | -788.70 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.75 | 0.75 | 2.03 | 2.38 | 1.88 | 2.69 | 5.03 | 5.47 | 4.82 | 0.54 | 3.16 |
| Quick Ratio | 0.75 | 0.75 | 2.03 | 2.38 | 1.88 | 2.69 | 5.03 | 5.47 | 4.82 | 0.54 | 3.16 |
| Cash Ratio | 0.54 | 0.54 | 1.71 | 1.93 | 1.41 | 2.02 | 3.87 | 4.62 | 4.39 | 0.40 | 2.89 |
| Asset Turnover | — | 0.33 | 0.12 | 0.04 | 0.05 | 0.12 | 0.04 | 0.04 | — | — | — |
| Inventory Turnover | — | — | 61.79 | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 13.45 | 116.57 | 609.72 | 665.41 | 339.02 | 1299.52 | 1019.10 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 1.7% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $80M | $70M | $56M | $45M | $44M | $38M | $33M | $19M | $9M | $19M |
Clinical Milestone Revenue Dependency
According to recent market data, MGTX trades at a P/S ratio of 13.78, a valuation that appears disconnected from the company's underlying clinical-stage status and reliance on lumpy, non-recurring milestone payments rather than sustainable commercial revenue streams.
The current valuation suggests that investors are pricing in significant optionality regarding the company's proprietary riboswitch platform rather than current financial performance. This multiple warrants caution, as it implies a high growth trajectory that may not be supported by the current, highly volatile revenue recognition cycle.
As reported in financial statements, the company's ROIC has fluctuated between -82.3% and 80.0% over the last ten quarters, reflecting a business model where capital is consumed rapidly to fund infrastructure and R&D rather than generating consistent returns on invested capital.
The extreme volatility in ROIC highlights the difficulty of assessing long-term compounding potential in a pre-commercial biotech firm. Investors should monitor whether the recent shift toward asset-based partnerships can stabilize these returns, or if the high fixed-cost manufacturing base will continue to drag on capital efficiency.
Based on historical data, the company's cash conversion cycle and asset turnover metrics remain highly erratic, with asset turnover frequently near zero, indicating that the firm's primary assets are not yet contributing to meaningful operational throughput or revenue generation.
The lack of consistent asset turnover suggests that the company's manufacturing facilities are currently underutilized relative to their cost basis. This inefficiency may persist until the company transitions from clinical development to commercial-scale production, at which point these metrics may provide a clearer picture of operational leverage.
As evidenced by the compression of the current ratio to 0.55 in 2026Q1, the company's liquidity position appears increasingly strained, leaving little margin for error in managing the high cash burn associated with its ongoing clinical trial programs.
The current liquidity profile suggests that the company may be forced to seek additional capital or divest further assets in the near term to maintain its current operational pace. This vulnerability is exacerbated by the lack of recurring revenue, which leaves the firm highly sensitive to any delays in milestone achievement.
The P/S ratio is the most commonly misapplied metric for MGTX, as it obscures the fact that revenue is derived from non-recurring milestone payments rather than sustainable product sales, leading to a potentially misleading assessment of the company's commercial health.
Investors should instead focus on the cash runway and the underlying burn rate, as these metrics provide a more accurate reflection of the company's survival and development capacity. Relying on revenue multiples in a pre-commercial context risks overestimating the company's current market position and financial stability.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MGTX stock.
MeiraGTx Holdings plc's current P/E ratio is -10.3x. This places it at the 50th percentile of its historical range.
MeiraGTx Holdings plc's return on equity (ROE) is -368.2%. The historical average is -157.4%.
Based on historical data, MeiraGTx Holdings plc is trading at a P/E of -10.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
MeiraGTx Holdings plc has 94.0% gross margin and -130.2% operating margin.